Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chemoresistance is one of the major obstacles in systemic chemotherapy and targeted therapy for patients with advanced
hepatocellular carcinoma
. To identify novel chemoresistance-associated targets in
hepatocellular carcinoma
, chemoresistant
hepatocellular carcinoma
cell lines were established. By comparing the global gene expression profiles between chemoresistant and chemosensitive cell lines, eight novel chemoresistance-associated genes were identified to be significantly associated with the commonly augmented chemoresistance of
hepatocellular carcinoma
cells. One upregulated candidate named
transmembrane protein 98
(
TMEM98
) was found to be overexpressed in 80 of 118 (67.80%) of patients with
hepatocellular carcinoma
.
TMEM98
mRNA in tumor tissues was significantly higher than nontumor tissues of patients with
hepatocellular carcinoma
(P < 0.0001). Upregulation of
TMEM98
was significantly correlated with advanced tumor stage (P = 0.048), high incidence of early tumor recurrence (P = 0.005), poor overall survival (P = 0.029), and poor disease-free survival (P = 0.011) of patients with
hepatocellular carcinoma
after hepatectomy. Importantly, upregulation of
TMEM98
mRNA in patients with
hepatocellular carcinoma
who received transarterial chemoembolization (TACE) treatment was significantly higher than in patients without TACE treatment (P = 0.046). Moreover, patients with poor response to TACE treatment had higher degree of
TMEM98
upregulation than the responsive patients. In vitro and in vivo studies showed that suppression of
TMEM98
in chemoresistant
hepatocellular carcinoma
cells restored their chemosensitivity, while forced overexpression of
TMEM98
enhanced their chemoresistance. The mechanism of
TMEM98
in conferring chemoresistance of
hepatocellular carcinoma
might be possibly through activation of the AKT pathway and deactivation of p53. In conclusion, we identified a panel of novel common chemoresistance-associated genes and demonstrated that
TMEM98
is a chemoresistance-conferring gene in
hepatocellular carcinoma
.
...
PMID:Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma. 2460 72
